CEO Ana Slipicevic present the MTHFD2 program and one-carbon therapeutics AB in the Hot Topic session at Bio€quity 2022 in Milan.
One-carbon therapeutics AB management at ESMO to discuss the ODIN clinical phase 1/2 trial with potential clinical sites across Europe
One-carbon therapeutics AB is discussing the ODIN trial with several